The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel ...

Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.

Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...

Initial results from dose escalation in the first in-human phase 1 trial of DS-9606 suggest early promising clinical activity in patients with advanced solid tumours known to express Claudin-6 (CLDN6) ...

Two of the world’s biggest drugmakers — AstraZeneca and MSD — have hailed progress in tackling hard-to-treat cancers, ...

The adaptive basket trial, which matches patients to treatments based on complex biomarker signatures, could help shape ...

TOKYO, Japan & BASKING RIDGE, NJ, USA I 15, 2024 I Initial results from dose escalation in the first-in-human phase 1 trial of DS-9606 suggest ...

MSD's Sac-TMT presents as a strong competitor to AstraZeneca/Daichii Sankyo's Dato-DXd based on cross-trial comparisons.

AstraZeneca's lung cancer drug datopotamab deruxtecan, called Dato-DXd, failed to show a significant benefit to overall survival when compared to docetaxel, a standard chemotherapy drug.